Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Leukemia Research|March 9, 2019
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibAaron T Gerds, Tetsuzo Tauchi, Ellen Ritchie, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
The Lancet. Haematology|August 27, 2021
Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNetAlberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, et al.
Cancer Medicine|April 10, 2026
Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial AnalysisRuben Mesa, Jeanne M Palmer, Francesca Palandri, et al.
Hematological Oncology|June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignanciesTariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Ejhaem|December 5, 2022
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosisNaveen Pemmaraju, Claire Harrison, Vikas Gupta, et al.
Haematologica|September 23, 2021
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Blood Cancer Journal|November 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosisMonia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, et al.
Leukemia & Lymphoma|October 21, 2014
Novel insights into the biology and treatment of chronic myeloproliferative neoplasmsTariq I Mughal, Tiziano Barbui, Omar Abdel-Wahab, et al.
British Journal of Haematology|November 19, 2016
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, et al.
Pageof 18